Sign In
Buy OBSV
$0.102
+0 (+0%)
At Close: Jun 21, 2023
ObsEva Announces Appointment of Luigi Marro as Chief Transformation Officer
01:00am, Thursday, 30'th Sep 2021
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange
ObsEva (OBSV) Files NDA for Linzagolix to Treat Uterine Fibroids
12:59pm, Wednesday, 15'th Sep 2021
ObsEva (OBSV) submits an NDA to the FDA for linzagolix as a potential treatment for uterine fibroids.
ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids
01:00am, Wednesday, 15'th Sep 2021
- If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of more women with uterine fibroids -
ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
01:00am, Tuesday, 07'th Sep 2021
GENEVA, Switzerland September 7 , 202 1 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, toda
5 Penny Stocks To Watch For September With Upcoming Events
02:15pm, Monday, 30'th Aug 2021
These penny stocks could be in focus as we turn the page on a new month. The post 5 Penny Stocks To Watch For September With Upcoming Events appeared first on Penny Stocks to Buy, Picks, News and Info
7 Hottest Penny Stocks to Pick Up Now
03:40pm, Tuesday, 10'th Aug 2021
Penny stocks from companies that have reasonable business fundamentals. Stocks that can possibly provide multi-fold returns.
ObsEva Announces Second Quarter 2021 Financial Results and Business Update
01:00am, Thursday, 05'th Aug 2021
- Linzagolix (Yselty ® ) for uterine fibroids: US New Drug Application filing planned in Q 3 :21 ; European marketing approval recommendation anticipated in Q4:21 -
- A Combined Analysis of Pregnancy and Live Birth in more than 1800 IVF Patient s Across Three Randomized , Placebo-Controlled Clinical Trials Published in the Journal of Human Reproduction-
ObsEva to Present at Upcoming Investor Conferences
01:00am, Tuesday, 03'rd Aug 2021
GENEVA, Switzerland August 3 , 202 1 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today a
OBSV Stock Increases Over 42% Intraday: Why It Happened
11:03am, Tuesday, 27'th Jul 2021
The stock price of Obseva SA (NASDAQ: OBSV) increased by over 42% during intraday trading. This is why it happened.
Every year, an estimated 15 million babies are born preterm (before 37 completed weeks of gestation) i ; agent is being studied in an area of significant unmet need
7 Penny Stocks For Your Watch List This Week If You Like Biotech In July
12:29pm, Monday, 05'th Jul 2021
Looking for biotech penny stocks to watch right now? Here are 7 for your list this week.
ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting
01:00am, Friday, 02'nd Jul 2021
-Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be presented in an ePoster and mini symposia –
-Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for uterine contractility of IVF patients prior to embryo transfe
